Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12586804 | 0.83 | CYP3A4 (0.40) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL12866043 | 0.81 | ALDH1A1 (0.42) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL1171938 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL27533953 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL30951061 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL24750296 | 0.79 | HPGD (0.36) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL31009327 | 0.79 | HPGD (0.36) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL10044946 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL15180075 | 0.77 | CA1 (0.47) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 | |
| SCHEMBL25845085 | 0.77 | POLB (0.44) | ALDH1A1CYP3A4SMN1; SMN2POLBALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| EP-1453492-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003045364-A2 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| EP-1313727-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | ALDH1A1 315/4885CYP3A4 2581/4885SMN1; SMN2 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.